Truist raises Eli Lilly stock price target on incretin strength

Truist raised its Eli Lilly (LLY) price target to $1,370 from $1,281 (Buy) on strong U.S. prescription growth for Zepbound and Mounjaro, expecting the company to beat 2Q 2026 estimates and raise guidance; however, it flagged slower-than-expected Foundayo growth. Separately, the EMA’s CHMP issued a positive opinion for Jaypirca (CLL), while Sandoz filed with the FDA for generic tirzepatide, potentially increasing competition. Cantor Fitzgerald lifted its LLY target to $1,350 (Overweight) and RBC reiterated $1,250 (Outperform), reinforcing a broadly constructive analyst setup despite some overvaluation signals.

Analysis

The key market issue is not whether the obesity franchise is good — it is whether current valuation already discounts a near-flawless multi-year uptake curve. When a stock is trading near peak multiples on peak growth, incremental analyst enthusiasm tends to matter less than any evidence of deceleration, reimbursement friction, or supply normalization; that creates a setup where even a clean beat can fail to translate into sustained upside.

The generic tirzepatide filing is the more important medium-term variable. Even if commercialization is distant, it starts a clock that can pressure terminal value, because payers, employers, and PBMs will negotiate as though price competition is inevitable. The first-order risk is not immediate unit loss; it is gross-to-net compression and a harder formulary battle in 12-24 months, especially if compounders or lower-cost alternatives remain in the channel.

Contrarian view: consensus is probably underweighting concentration risk. The obesity story is still carrying the stock, while the rest of the portfolio is not yet large enough to offset any stumble in that engine; Jaypirca is optionality, not a substitute. Falsifier for a bearish relative-value view: sustained upside in U.S. prescription growth plus clearer evidence that generic entry is delayed well beyond the market’s current timeline. If that does not happen, LLY remains a great company but a vulnerable stock at this price.

Key Decisions for Investors

• Long ABBV / short LLY as a 3-6 month relative-value pair: ABBV offers lower concentration risk and less multiple fragility, while LLY is priced for continued perfection. Use a 5-10% portfolio-neutral spread and cut the short if LLY raises full-year guidance again with accelerating U.S. obesity scripts.
• Buy a defined-risk LLY put spread 4-6 months out on any strength-driven pop: the thesis is valuation compression, not a collapse in fundamentals. Target roughly 10-15% downside; risk is limited premium if the stock re-rates on another upside surprise.
• Do not chase SDZNY yet; make it a watchlist trade tied to patent/litigation or FDA milestones. If the generic path becomes legally cleaner, SDZNY becomes a tactical long and LLY a better short, but the timing is too uncertain today.
• If you want cleaner sector exposure, rotate out of LLY into a basket of lower-beta large-cap pharma rather than broad biotech. The catalyst path is 1-3 months of headline noise versus 6-18 months of pricing pressure, so prefer names with less binary terminal-value risk.